Fig. 8: Anti-tumor effect of combination of ML323 and TRAIL in xenograft model. | Cell Death & Disease

Fig. 8: Anti-tumor effect of combination of ML323 and TRAIL in xenograft model.

From: Inhibition of USP1 enhances anticancer drugs-induced cancer cell death through downregulation of survivin and miR-216a-5p-mediated upregulation of DR5

Fig. 8

A–C Mice bearing HCT116 cells were treated with 10 mg/kg ML323, 3 mg/kg GST-TRAIL, combinations, or vehicle (i.p.) for 21 days. Tumor volume and size were measured (A). Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) assays were performed to check apoptosis in vivo. scale bar: 50 μm (B). Protein expression was measured by western blot analysis (C). D Examination of survivin and DR5 protein expression in 40 paired primary RCC tissues and corresponding normal adjacent tissues. E Correlation analysis of protein expression of USP1/survivin. F Examination of DR5 (left panel) and miR-216a-5p (right panel) mRNA expression in 40 paired primary renal cancer cell (RCC) tissues and corresponding normal adjacent tissues. G Analysis of prognostic significance of survivin and DR5 in RCC patients based on TCGA. *P < 0.01 compared to the vehicle. i.p. intraperitoneal injection.

Back to article page